Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (301-310 of 539) with videos related to

Pageof 54
Sort By:
Blood|February 29, 2020
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuriaChristoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Haematologica|May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow upUte Hegenbart, Tilmann Bochtler, Axel Benner, et al.
Haematologica|August 24, 2019
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma NetworkPhilippe Moreau, Pieter Sonneveld, Mario Boccadoro, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2023
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple MyelomaMaría-Victoria Mateos, Ajai Chari, Saad Z Usmani, et al.
Blood|March 21, 2009
Induction of angiogenesis by normal and malignant plasma cellsDirk Hose, Jérôme Moreaux, Tobias Meissner, et al.
Academic Radiology|January 23, 2025
Advanced Automated Model for Robust Bone Marrow Segmentation in Whole-body MRIFabian Bauer, Jessica Kächele, Juliane Bernhard, et al.
Cancers|December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German RegistryMaximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
Hemasphere|February 8, 2021
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-upMeletios A Dimopoulos, Philippe Moreau, Evangelos Terpos, et al.
European Journal of Haematology|April 5, 2017
Genomewide association study on monoclonal gammopathy of unknown significance (MGUS)Hauke Thomsen, Chiara Campo, Niels Weinhold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trialsPieter Sonneveld, Hartmut Goldschmidt, Laura Rosiñol, et al.
Pageof 54

Showing results (301-310 of 539) with videos related to

Sort By:
Pageof 54
Blood|February 29, 2020
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuriaChristoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Haematologica|May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow upUte Hegenbart, Tilmann Bochtler, Axel Benner, et al.
Haematologica|August 24, 2019
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma NetworkPhilippe Moreau, Pieter Sonneveld, Mario Boccadoro, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2023
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple MyelomaMaría-Victoria Mateos, Ajai Chari, Saad Z Usmani, et al.
Blood|March 21, 2009
Induction of angiogenesis by normal and malignant plasma cellsDirk Hose, Jérôme Moreaux, Tobias Meissner, et al.
Academic Radiology|January 23, 2025
Advanced Automated Model for Robust Bone Marrow Segmentation in Whole-body MRIFabian Bauer, Jessica Kächele, Juliane Bernhard, et al.
Cancers|December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German RegistryMaximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
Hemasphere|February 8, 2021
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-upMeletios A Dimopoulos, Philippe Moreau, Evangelos Terpos, et al.
European Journal of Haematology|April 5, 2017
Genomewide association study on monoclonal gammopathy of unknown significance (MGUS)Hauke Thomsen, Chiara Campo, Niels Weinhold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trialsPieter Sonneveld, Hartmut Goldschmidt, Laura Rosiñol, et al.
Pageof 54